GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Cyclically Adjusted Price-to-FCF

Antengene (HKSE:06996) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Antengene Cyclically Adjusted Price-to-FCF?

Antengene does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Antengene Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Antengene's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Cyclically Adjusted Price-to-FCF Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial - - - - -

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Antengene's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Antengene's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antengene's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Antengene's Cyclically Adjusted Price-to-FCF falls into.


;
;

Antengene Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Antengene does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.


Antengene  (HKSE:06996) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Antengene Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Antengene's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Antengene Business Description

Industry
Traded in Other Exchanges
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
Executives
Xyxy Holdings Ltd. 2201 Interest of corporation controlled by you
Boyu Group, Llc 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Tong Xiaomeng 2201 Interest of corporation controlled by you
Jay Mei 2025 Grat 2201 Interest of corporation controlled by you
Mei Jay 2201 Interest of corporation controlled by you
Jay Mei 2023 Grat 2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Gp3 Ltd. 2201 Interest of corporation controlled by you
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Fountainvest China Capital Partners Fund Iii, L.p. 2201 Interest of corporation controlled by you
Begonia Investment Ltd. 2101 Beneficial owner
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner

Antengene Headlines

No Headlines